CDCD47: A Protein Interaction in Cell Signaling Processes (G57003)

Target Name: CCDC47

NCBI ID: G57003

CCDC47

CDCD47: A Protein Interaction in Cell Signaling Processes

CCDC47, also known as Calumin, is a protein that is expressed in various tissues throughout the body. It is a member of the calbindin family of proteins, which are involved in the regulation of cell signaling processes. Calbindin is a widely used biomarker for various diseases, including cancer, because of its ability to be easily measured and to react to changes in cellular activity.

One of the unique features of CCDC47 is its ability to interact with various signaling molecules, including TGF-β1. TGF-β1 is a key transcription factor that is involved in the regulation of cellular processes that are critical for growth, differentiation, and repair. When TGF-β1 is activated, it causes the cell to enter a state of increased sensitivity to mechanical forces, which can lead to the development of various diseases, including cancer.

In addition to its role in TGF-β1 signaling, CCDC47 has also been shown to play a role in the regulation of cellular signaling processes that are important for cell survival. For example, studies have shown that CCDC47 can interact with the protein p53, which is a tumor suppressor protein that is involved in the regulation of cellular processes that are critical for cell growth and division. When p53 is activated, it causes the cell to enter a state ofDNA damage repair, which is important for the regulation of cellular growth and the prevention of cancer.

Another study has shown that CCDC47 can interact with the protein NF-kappa-B, which is a signaling molecule that is involved in the regulation of cellular processes that are important for inflammation and pain. When NF-kappa-B is activated, it causes the cell to enter a state of inflammation, which can lead to the development of various diseases, including cancer.

In conclusion, CCDC47 is a protein that is involved in a variety of cellular signaling processes that are important for cell survival and regulation. Its interaction with TGF-β1, p53, and NF-kappa-B suggests that it may be a potential drug target or biomarker for various diseases, including cancer. Further research is needed to fully understand the role of CCDC47 in cellular signaling processes and its potential as a drug or biomarker.

Protein Name: Coiled-coil Domain Containing 47

Functions: Component of the multi-pass translocon (MPT) complex that mediates insertion of multi-pass membrane proteins into the lipid bilayer of membranes (PubMed:32814900, PubMed:32820719, PubMed:36261522). The MPT complex takes over after the SEC61 complex: following membrane insertion of the first few transmembrane segments of proteins by the SEC61 complex, the MPT complex occludes the lateral gate of the SEC61 complex to promote insertion of subsequent transmembrane regions (PubMed:36261522). Within the MPT complex, the PAT subcomplex sequesters any highly polar regions in the transmembrane domains away from the non-polar membrane environment until they can be buried in the interior of the fully assembled protein (By similarity). Within the PAT subcomplex, CCDC47 occludes the lateral gate of the SEC61 complex (By similarity). Involved in the regulation of calcium ion homeostasis in the ER (PubMed:30401460). Required for proper protein degradation via the ERAD (ER-associated degradation) pathway (PubMed:25009997). Has an essential role in the maintenance of ER organization during embryogenesis (By similarity)

The "CCDC47 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CCDC47 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets